

Revision date: 17-Jun-2010 Version: 1.2 Page 1 of 8

IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Pfizer Inc **Pfizer Pharmaceuticals Group** 235 East 42nd Street New York, New York 10017 1-212-573-2222

Emergency telephone number: CHEMTREC (24 hours): 1-800-424-9300 **Contact E-Mail:** pfizer-MSDS@pfizer.com Pfizer Ltd Ramsgate Road Sandwich, Kent **CT13 9NJ United Kingdom** +00 44 (0)1304 616161

Emergency telephone number:

ChemSafe (24 hours): +44 (0)208 762 8322

Material Name: Trimethoprim/Sulfametopyrazine Capsules

Trade Name: KELFIPRIM®; TRIDIS®

Chemical Family: Mixture

Intended Use: Pharmaceutical product used as antibiotic agent

2. HAZARDS IDENTIFICATION

Gray and yellow capsules Appearance:

Signal Word: DANGER

Statement of Hazard: Toxic if swallowed.

Suspected of damaging the unborn child.

Additional Hazard Information:

May be harmful if swallowed. (based on animal data) . **Short Term:**

Long Term: Animal studies have shown a potential to cause adverse effects on the fetus.

Known Clinical Effects: Adverse effects associated with therapeutic use include nausea, diarrhea, blood cell changes,

muscle pain, skin rash, Stevens Johnson Syndrome (epidermal necrosis and exfoliative dermatitis), kidney toxicity (nephrotoxicity). Clinical use has resulted in changes in electrolytes and/or blood chemistry changes. Individuals sensitive to this material or other materials in its

chemical class may develop allergic reactions.

Toxic **EU Indication of danger:**

Toxic to Reproduction: Category 3

EU Hazard Symbols:

EU Risk Phrases:

R25 - Toxic if swallowed.

R63 - Possible risk of harm to the unborn child. Hazardous Substance. Non-Dangerous Goods.

Australian Hazard Classification (NOHSC):

PZ00261

Material Name: Trimethoprim/Sulfametopyrazine Capsules

Revision date: 17-Jun-2010 Version: 1.2

2. HAZARDS IDENTIFICATION

Note:

This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

Page 2 of 8

3. COMPOSITION/INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	%
Maize starch	9005-25-8	232-679-6	Not Listed	*
Talc (non-asbestiform)	14807-96-6	238-877-9	Not Listed	*
Trimethoprim	738-70-5	212-006-2	T;R25	50
			Repr.Cat.3;R63	
Sulfadiazine	68-35-9	200-685-8	Not Listed	40
Magnesium Stearate	557-04-0	209-150-3	OEL	*

Additional Information: * Proprietary

Ingredient(s) indicated as hazardous have been assessed under standards for workplace

safety.

4. FIRST AID MEASURES

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention

immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek

medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not

induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards

Identification and/or Section 11 - Toxicological Information.

5. FIRE FIGHTING MEASURES

Extinguishing Media: Use carbon dioxide, dry chemical, or water spray.

Hazardous Combustion Products: Emits fumes of carbon dioxide sulfur oxides nitrogen oxides

Fire Fighting Procedures: During all fire fighting activities, wear appropriate protective equipment, including self-

contained breathing apparatus.

Fire / Explosion Hazards: Not applicable

6. ACCIDENTAL RELEASE MEASURES

Health and Safety Precautions: Personnel involved in clean-up should wear appropriate personal protective equipment (see

Section 8). Minimize exposure.

P700004

Material Name: Trimethoprim/Sulfametopyrazine Capsules

Revision date: 17-Jun-2010 Version: 1.2

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spilled material by a method that

controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of

Page 3 of 8

dry solids. Clean spill area thoroughly.

Measures for Environmental

Protections:

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to

avoid environmental release.

Additional Consideration for Large

Spills:

Non-essential personnel should be evacuated from affected area. Report emergency

situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Minimize dust generation and accumulation. If tablets or capsules are crushed and/or broken, **General Handling:**

avoid breathing dust and avoid contact with eyes, skin, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or

other equivalent controls.

Storage Conditions: Store as directed by product packaging.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Refer to available public information for specific member state Occupational Exposure Limits.

Maize starch

ACGIH Threshold Limit Value (TWA) 10 mg/m³ TWA **Australia TWA** 10 mg/m³ **Belgium OEL - TWA** Listed **Bulgaria OEL - TWA** Listed Czech Republic OEL - TWA Listed **Greece OEL - TWA** Listed Ireland OEL - TWAs Listed **OSHA - Final PELS - TWAs:** 15 mg/m3 total

5 mg/m³ Portugal OEL - TWA Listed

Spain OEL - TWA Listed

Talc (non-asbestiform)

2 mg/m³ TWA **ACGIH Threshold Limit Value (TWA)**

ACGIH OELs - Notice of Intended Changes Listed

Australia TWA 2.5 mg/m³ containing no asbestos fibers

Austria OEL - MAKs Listed **Belgium OEL - TWA** Listed **Bulgaria OEL - TWA** Listed Czech Republic OEL - TWA Listed Listed **Denmark OEL - TWA Estonia OEL - TWA** Listed **Finland OEL - TWA** Listed **Greece OEL - TWA** Listed **Hungary OEL - TWA** Listed **Ireland OEL - TWAs** Listed Listed **Netherlands OEL - TWA**

Material Name: Trimethoprim/Sulfametopyrazine Capsules Page 4 of 8
Revision date: 17-Jun-2010 Version: 1.2

15555

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

OSHA - Final PELs - Table Z-3 Mineral D: TWA-20 mppcf

Poland OEL - TWA Listed
Portugal OEL - TWA Listed
Romania OEL - TWA Listed
Slovenia OEL - TWA Listed
Spain OEL - TWA Listed
Sweden OEL - TWAS Listed

Trimethoprim

Pfizer OEL TWA-8 Hr: 100µg/m³

Sulfadiazine

Pfizer OEL TWA-8 Hr: 2000µg/m³
Lithuania OEL - TWA Listed

Magnesium Stearate

ACGIH Threshold Limit Value (TWA) 10 mg/m³ TWA **Australia TWA** 10 mg/m³ **Belgium OEL - TWA** Listed **Ireland OEL - TWAs** Listed Lithuania OEL - TWA Listed Listed Portugal OEL - TWA Spain OEL - TWA Listed Listed **Sweden OEL - TWAs**

Analytical Method: Analytical method available for sulfadiazine; trimethoprin. Contact Pfizer Inc for further

information.

Engineering Controls: Engineering controls should be used as the primary means to control exposures. General

room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne

contamination levels below the exposure limits listed above in this section.

Environmental Exposure Controls: Refer to specific Member State legislation for requirements under Community environmental

legislation.

Personal Protective Equipment: Refer to applicable national standards and regulations in the selection and use of personal

protective equipment (PPE).

Hands: Impervious gloves are recommended if skin contact with drug product is possible and for bulk

processing operations.

Eyes: Wear safety glasses or goggles if eye contact is possible.

Skin: Impervious protective clothing is recommended if skin contact with drug product is possible and

for bulk processing operations.

Respiratory protection: If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate

respirator with a protection factor sufficient to control exposures to below the OEL.

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Capsule Color: Gray and yellow

Molecular Formula: Mixture Molecular Weight: Mixture

P700004

Page 5 of 8

Material Name: Trimethoprim/Sulfametopyrazine Capsules

Revision date: 17-Jun-2010 Version: 1.2

10. STABILITY AND REACTIVITY

Chemical Stability: Stable under normal conditions of use.

Conditions to Avoid: None known

Incompatible Materials: As a precautionary measure, keep away from strong oxidizers

11. TOXICOLOGICAL INFORMATION

General Information: The information included in this section describes the potential hazards of the individual

ingredients.

Acute Toxicity: (Species, Route, End Point, Dose)

Trimethoprim

Rat Oral LD50 200 mg/kg

Rat Sub-tenon injection (eye) LD50 500 mg/kg

Mouse Oral LD50 2764 mg/kg
Mouse Intravenous LD50 200 mg/kg
Mouse Intraperitoneal LD50 1870 mg/kg

Sulfadiazine

Mouse Oral LD 50 1500 mg/kg

Talc (non-asbestiform)

Rat Oral LD50 > 1600 mg/kg

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable

at the highest dose used in the test.

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Magnesium Stearate

13 Week(s) Rat Oral 1092 g/kg LOAEL Liver

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Trimethoprim

70 mg/kg/day Oral Fertility Reproductive & Fertility-Males Rat NOAEL Reproductive & Fertility - Females Rat Oral 14 mg/kg/day NOAEL **Fertility** Embryo / Fetal Development Rabbit Oral 30 mg/kg LOAEL Embryotoxicity

Embryo / Fetal Development Rat Oral 200 mg/kg LOAEL Maternal Toxicity, Teratogenic

Embryo / Fetal Development Mouse Oral 70 mg/kg NOAEL Not Teratogenic

Sulfadiazine

Embryo / Fetal Development Rat Oral 500 mg/kg/day NOEL Not teratogenic Embryo / Fetal Development Mouse Oral 500 mg/kg/day NOEL Not Teratogenic Reproductive & Fertility Rabbit 250 mg/kg/day NOEL Not Teratogenic Oral

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Trimethoprim

Bacterial Mutagenicity (Ames) Salmonella, E. coli Negative

In Vitro Chromosome Aberration Chinese Hamster Ovary (CHO) cells Negative

In Vitro Chromosome Aberration Human Lymphocytes Negative

PZ00261

Material Name: Trimethoprim/Sulfametopyrazine Capsules

Revision date: 17-Jun-2010 Version: 1.2

11. TOXICOLOGICAL INFORMATION

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

See below

Talc (non-asbestiform)

IARC: Group 3

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been thoroughly investigated. Releases to the environment

should be avoided.

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

Trimethoprim

Daphnia magna (Water Flea) OECD LC50 48 Hours 141 mg/L

Sulfadiazine

Selenastrum capricornutum (Green Alga) OECD EC50 72 Hours 3.43 mg/L

Daphnia magna (Water Flea) OECD EC50 48 Hours 88.0 mg/L

Oncorhynchus mykiss (Rainbow Trout) OECD LC50 96 Hours 103.0 mg/L

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State

specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental

Page 6 of 8

releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

EU Symbol: T **EU Indication of danger:** Toxic

Toxic to Reproduction: Category 3

EU Risk Phrases:

R25 - Toxic if swallowed.

R63 - Possible risk of harm to the unborn child.

EU Safety Phrases:

Material Name: Trimethoprim/Sulfametopyrazine Capsules

Revision date: 17-Jun-2010 Version: 1.2

15. REGULATORY INFORMATION

S22 - Do not breathe dust.

S28 - After contact with skin, wash immediately with plenty of water.

S36/37 - Wear suitable protective clothing and gloves.

S45 - In case of accident or if you feel unwell, seek medical advice immediately (show the label where possible).

Page 7 of 8

S53 - Avoid exposure - obtain special instructions before use.

OSHA Label:

DANGER

Toxic if swallowed.

Suspected of damaging the unborn child.

Canada - WHMIS: Classifications

WHMIS hazard class:

Class D, Division 1, Subdivision B Class D, Division 2, Subdivision A



Maize starch

Inventory - United States TSCA - Sect. 8(b)ListedAustralia (AICS):ListedREACH - Annex IV - Exemptions from thePresent

obligations of Register:

EU EINECS/ELINCS List 232-679-6

Talc (non-asbestiform)

Inventory - United States TSCA - Sect. 8(b)ListedAustralia (AICS):ListedEU EINECS/ELINCS List238-877-9

Trimethoprim

Australia (AICS): Listed
Standard for the Uniform Scheduling Schedule 4

for Drugs and Poisons:

EU EINECS/ELINCS List 212-006-2

Sulfadiazine

Inventory - United States TSCA - Sect. 8(b)ListedAustralia (AICS):ListedStandard for the Uniform Scheduling
for Drugs and Poisons:Schedule 4EU EINECS/ELINCS List200-685-8

Magnesium Stearate

Inventory - United States TSCA - Sect. 8(b)

Listed

Material Name: Trimethoprim/Sulfametopyrazine Capsules

Revision date: 17-Jun-2010 Version: 1.2

15. REGULATORY INFORMATION

Australia (AICS): Listed EU EINECS/ELINCS List 209-150-3

16. OTHER INFORMATION

Text of R phrases mentioned in Section 3

R25 - Toxic if swallowed.

R63 - Possible risk of harm to the unborn child.

Data Sources: Safety data sheets for individual ingredients. Pfizer proprietary drug development information.

Reasons for Revision: Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on

Ingredients. Updated Section 4 - First Aid Measures. Updated Section 5 - Fire Fighting Measures. Updated Section 6 - Accidental Release Measures. Updated Section 7 - Handling and Storage. Updated Section 8 - Exposure Controls / Personal Protection. Updated Section

Page 8 of 8

15 - Regulatory Information.

Prepared by: Product Stewardship Hazard Communications

Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet
